| Literature DB >> 30113467 |
Sorin Albu1, Septimiu Voidazan, Doina Bilca, Monica Badiu, Andreea Truţă, Marian Ciorea, Alin Ichim, Diana Luca, Geanina Moldovan.
Abstract
Urinary tract infections due to the presence of a urinary catheter represent a real problem for patients who have to carry such an invasive device for a long time.Our aim was to identify the susceptibility of extended spectrum beta lactamases (ESBL) versus non-ESBL bacteria to antibiotics in urinary tract infections in patients who are chronic carriers of urinary catheters.The retrospective study included a period of 5 years, a total of 405 patients who are chronic carriers of urinary catheters, admitted to rehabilitation and palliative care units.Escherichia coli (E coli) was isolated in 41.2% of patients, Klebsiella pneumoniae (K pneumoniae) in 24.7%, and Proteus mirabilis (P mirabilis) in 15.3%. E coli microbial resistance rates ranged from a minimum of 7.5% (nitrofurantoin) to a maximum of 77.1% (ampicillin). In the case of K pneumoniae, microbial resistance ranged from 34.2% (netilmicin) to 73.2% (ceftriaxone). Resistance rates of P mirabilis ranged from 11.1% (cefepim) to 89.5% (ampicillin). Positivity of ESBL bacteria was identified in 47.4% of patients. Resistance rates of ESBL-positive E coli ranged from 50.0% (ceftriaxone) to 88.1% (cefepime), and ESBL-negative E coli rates ranged from 3.4% (cefepime) to 64.4% (amikacin). Resistance rates of ESBL-positive K pneumoniae ranged between 39.1% (netilmicin) and 85.1% (ceftriaxone), and ESBL-negative K pneumoniae between 7.1% (cefepime) and 53.3% (amikacin). In cases of ESBL-positive P mirabilis, rates ranged from 13.3% (cefepime) to 90.3% (ceftriaxone), whereas in cases of ESBL-negative P mirabilis, rates ranged between 8.3% (cefepime) and 80.0% (trimetroprim).Bacteriuria and asymptomatic catheter infection in chronic carriers is an important public health concern due to the frequent presence of multidrug-resistant bacteria. Our study highlights the need to develop control programs of catheter infections to minimize the risk of infections associated with these medical devices, and also the need for treatment of the infection rather than catheter colonization or contamination.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30113467 PMCID: PMC6112905 DOI: 10.1097/MD.0000000000011796
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.889
Characteristics of the patients.
Results of antimicrobial agents producing uropathogenic. Escherichia coli (E coli), Klebsiella pneumonia (K pneumonia), Proteus mirabilis (P mirabilis), or Pseudomonas Aeruginosa (P aeruginosa).
Figure 1Antibiotic susceptibility testing of ESBL versus non-ESBL bacteria. ESBL = extended spectrum beta lactamases.
Figure 2Antibiotic susceptibility testing of ESBL E coli versus non-ESBL E coli. E coli = Escherichia coli, ESBL = extended spectrum beta lactamases.
Figure 3Antibiotic susceptibility testing of ESBL K pneumoniae versus non-ESBL K pneumoniae., K ESBL = extended spectrum beta lactamasespneumoniae = Klebsiella pneumoniae.
Figure 4Antibiotic susceptibility testing of ESBL P mirabilis versus non-ESBL P mirabilis. ESBL = extended spectrum beta lactamases, P mirabilis = Proteus mirabilis.